Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.71 |
| ▸ | FAP | Q12884 | 3/20 | 0.70 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.70 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.70 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048286 | 0.84 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL17048338 | 0.84 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL17048339 | 0.84 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL15024754 | 0.83 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12354534 | 0.83 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3189715 | 0.83 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL15855961 | 0.83 | DPP4 (0.69) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL26377731 | 0.83 | DPP4 (0.51) | DPP4FAPDPP8DPP9DPP7 | |
| Vildagliptin SCHEMBL665401 | 0.82 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 0.82 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-02 | — | — | US | disclosed |
| US-20200046713-A1 | TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | disclosed |
| US-10022379-B2 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20170173027-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170119773-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| EP-2590943-B1 | PROCESS AND INTERMEDIATES FOR PREPARATION OF AN ACTIVE INGREDIENT | CHEMELECTIVA SRL (IT) | 2014-10-01 | — | — | EP | disclosed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20080167479-A1 | PROCESS FOR PREPARING VILDAGLIPTIN | MEDICHEM, S.A. (ES) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | PROC, F2, F8 | DPP4 4599/4885FAP 612/4885DPP8 4167/4885 |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 365/4885DPP8 15/4885 |
| US-20200046713-A1 | TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN | DPP4, DPP3, DPP9 | DPP4 1/4885FAP 53/4885DPP8 5/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885FAP 882/4885DPP8 41/4885 |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885FAP 127/4885DPP8 19/4885 |
| US-10022379-B2 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885DPP8 5/4885 |
| US-20080167479-A1 | PROCESS FOR PREPARING VILDAGLIPTIN | VIL1, VIP, DPP7 | DPP4 4/4885FAP 164/4885DPP8 9/4885 |
| US-20170119773-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885DPP8 5/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 366/4885DPP8 10/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 416/4885DPP8 11/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885FAP 939/4885DPP8 28/4885 |
| US-20170173027-A1 | ANTIDIABETIC MEDICATIONS | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885FAP 1562/4885DPP8 14/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | DPP4 9/4885FAP 799/4885DPP8 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.